Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 11/20 | 0.45 |
| ▸ | CA1 | P00915 | 11/20 | 0.45 |
| ▸ | CA2 | P00918 | 11/20 | 0.45 |
| ▸ | CA9 | Q16790 | 11/20 | 0.45 |
| ▸ | CA4 | P22748 | 6/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243646 | 0.88 | EPHX2 (0.41) | EPHX2 | |
| SCHEMBL10244285 | 0.81 | ESR1 (0.42) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL10243765 | 0.78 | KMT2A (0.48) | ALDH1A1GAA | |
| SCHEMBL334879 | 0.78 | ALDH1A1 (0.62) | ALDH1A1EPHX2CA12CA1CA2 | |
| SCHEMBL10243724 | 0.78 | KMT2A (0.44) | ALDH1A1GAA | |
| SCHEMBL10244323 | 0.75 | SLC22A3 (0.51) | GAA | |
| SCHEMBL10244522 | 0.73 | RRM1 (0.42) | ALDH1A1 | |
| SCHEMBL10243815 | 0.73 | KMT2A (0.41) | ALDH1A1MAPK1 | |
| SCHEMBL10243841 | 0.73 | ADRB2 (0.39) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL10243752 | 0.72 | POLB (0.48) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | ALDH1A1 1939/4885EPHX2 2656/4885CA12 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.